デフォルト表紙
市場調査レポート
商品コード
966660

抗炎症薬 - 市場考察、疫学、市場予測:2030年

Anti-inflammatory - Market Insight, Epidemiology and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 200 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
抗炎症薬 - 市場考察、疫学、市場予測:2030年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、抗炎症薬について調査分析し、過去・将来の疫学、米国・欧州5ヶ国 (ドイツ、スペイン、イタリア、フランス、英国) ・日本の市場動向に焦点を当てて、現在の治療法、新薬、市場規模などについて、体系的な情報を提供しています。

目次

第1章 主要考察

第2章 抗炎症薬のエグゼクティブサマリー

第3章 抗炎症薬の競合情勢

第4章 抗炎症薬:市場概要

  • 2017年の抗炎症薬の市場シェア分布
  • 2030年の抗炎症薬の市場シェア分布

第5章 抗炎症薬:疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理
  • 危険因子
  • 診断

第6章 ペイシェントジャーニー

第7章 抗炎症薬の疫学と患者集団

  • 疫学の主な調査結果
  • 前提条件と根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
  • 米国の疫学
  • 欧州5ヶ国の国別疫学

第8章 治療アルゴリズム、現在の治療、医療業務

  • 抗炎症薬の治療と管理
  • 抗炎症薬の治療アルゴリズム

第9章 アンメットニーズ

第10章 抗炎症薬の治療の主要評価項目

第11章 上市薬

第12章 新薬

第13章 抗炎症薬:主要7ヶ国市場分析

  • 主な調査結果
  • 主要7ヶ国の抗炎症薬の市場規模
  • 主要7ヶ国の抗炎症薬の市場規模:治療別

第14章 属性分析

第15章 主要7ヶ国:市場の見通し

  • 米国:市場規模
  • 欧州5ヶ国:市場規模と見通し
  • ドイツの市場規模
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模
  • 日本の市場の見通し

第16章 抗炎症薬の市場参入と償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: 7MM Anti-inflammatory Epidemiology (2017-2030)
  • Table 2: 7MM Anti-inflammatory Diagnosed and Treatable Cases (2017-2030)
  • Table 3: Anti-inflammatory Epidemiology in the United States (2017-2030)
  • Table 4: Anti-inflammatory Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Anti-inflammatory Epidemiology in Germany (2017-2030)
  • Table 6: Anti-inflammatory Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Anti-inflammatory Epidemiology in France (2017-2030)
  • Table 8: Anti-inflammatory Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Anti-inflammatory Epidemiology in Italy (2017-2030)
  • Table 10: Anti-inflammatory Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Anti-inflammatory Epidemiology in Spain (2017-2030)
  • Table 12: Anti-inflammatory Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Anti-inflammatory Epidemiology in the UK (2017-2030)
  • Table 14: Anti-inflammatory Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: Anti-inflammatory Epidemiology in Japan (2017-2030)
  • Table 16: Anti-inflammatory Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Anti-inflammatory Epidemiology (2017-2030)
  • Figure 2: 7MM Anti-inflammatory Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: Anti-inflammatory Epidemiology in the United States (2017-2030)
  • Figure 4: Anti-inflammatory Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Anti-inflammatory Epidemiology in Germany (2017-2030)
  • Figure 6: Anti-inflammatory Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Anti-inflammatory Epidemiology in France (2017-2030)
  • Figure 8: Anti-inflammatory Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Anti-inflammatory Epidemiology in Italy (2017-2030)
  • Figure 10: Anti-inflammatory Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Anti-inflammatory Epidemiology in Spain (2017-2030)
  • Figure 12: Anti-inflammatory Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Anti-inflammatory Epidemiology in the UK (2017-2030)
  • Figure 14: Anti-inflammatory Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: Anti-inflammatory Epidemiology in Japan (2017-2030)
  • Figure 16: Anti-inflammatory Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.

目次
Product Code: DIMI1063

DelveInsight's "Anti-inflammatory - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Anti-inflammatory, historical and forecasted epidemiology as well as the Anti-inflammatory market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Anti-inflammatory market report provides current treatment practices, emerging drugs, Anti-inflammatory market share of the individual therapies, current and forecasted Anti-inflammatory market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Anti-inflammatory treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Anti-inflammatory Disease Understanding and Treatment Algorithm

The DelveInsight Anti-inflammatory market report gives a thorough understanding of the Anti-inflammatory by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Anti-inflammatory.

Treatment

It covers the details of conventional and current medical therapies available in the Anti-inflammatory market for the treatment of the condition. It also provides Anti-inflammatory treatment algorithms and guidelines in the United States, Europe, and Japan.

Anti-inflammatory Epidemiology

The Anti-inflammatory epidemiology division provide insights about historical and current Anti-inflammatory patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Anti-inflammatory epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Anti-inflammatory Epidemiology

The epidemiology segment also provides the Anti-inflammatory epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anti-inflammatory Drug Chapters

Drug chapter segment of the Anti-inflammatory report encloses the detailed analysis of Anti-inflammatory marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Anti-inflammatory clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Anti-inflammatory treatment.

Anti-inflammatory Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Anti-inflammatory treatment.

Anti-inflammatory Market Outlook

The Anti-inflammatory market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Anti-inflammatory market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Anti-inflammatory market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Anti-inflammatory market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Anti-inflammatory market in 7MM.

The United States Market Outlook

This section provides the total Anti-inflammatory market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Anti-inflammatory market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Anti-inflammatory market size and market size by therapies in Japan is also mentioned.

Anti-inflammatory Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Anti-inflammatory market or expected to get launched in the market during the study period 2017-2030. The analysis covers Anti-inflammatory market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Anti-inflammatory Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Anti-inflammatory key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Anti-inflammatory emerging therapies.

Reimbursement Scenario in Anti-inflammatory

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Anti-inflammatory domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anti-inflammatory market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Anti-inflammatory Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Anti-inflammatory, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Anti-inflammatory epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Anti-inflammatory are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Anti-inflammatory market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anti-inflammatory market

Report Highlights:

  • In the coming years, Anti-inflammatory market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anti-inflammatory R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Anti-inflammatory. Launch of emerging therapies will significantly impact the Anti-inflammatory market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anti-inflammatory
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Anti-inflammatory Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Anti-inflammatory Pipeline Analysis
  • Anti-inflammatory Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Anti-inflammatory Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Anti-inflammatory Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Anti-inflammatory Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Anti-inflammatory market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Anti-inflammatory total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Anti-inflammatory market size during the forecast period (2017-2030)?
  • At what CAGR, the Anti-inflammatory market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Anti-inflammatory market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Anti-inflammatory market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Anti-inflammatory?
  • What is the historical Anti-inflammatory patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Anti-inflammatory in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anti-inflammatory?
  • Out of all 7MM countries, which country would have the highest prevalent population of Anti-inflammatory during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Anti-inflammatory treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Anti-inflammatory in the USA, Europe, and Japan?
  • What are the Anti-inflammatory marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Anti-inflammatory ?
  • How many therapies are developed by each company for Anti-inflammatory treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Anti-inflammatory treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Anti-inflammatory therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anti-inflammatory and their status?
  • What are the key designations that have been granted for the emerging therapies for Anti-inflammatory ?
  • What are the global historical and forecasted market of Anti-inflammatory?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Anti-inflammatory market
  • To understand the future market competition in the Anti-inflammatory market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Anti-inflammatory in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Anti-inflammatory market
  • To understand the future market competition in the Anti-inflammatory market

Table of Contents

1. Key Insights

2. Executive Summary of Anti-inflammatory

3. Competitive Intelligence Analysis for Anti-inflammatory

4. Anti-inflammatory: Market Overview at a Glance

  • 4.1. Anti-inflammatory Total Market Share (%) Distribution in 2017
  • 4.2. Anti-inflammatory Total Market Share (%) Distribution in 2030

5. Anti-inflammatory: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Anti-inflammatory Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Anti-inflammatory Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Anti-inflammatory Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Anti-inflammatory Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Anti-inflammatoryEpidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Anti-inflammatory Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Anti-inflammatory Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Anti-inflammatory Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Anti-inflammatory Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Anti-inflammatory Treatment and Management
  • 8.2. Anti-inflammatory Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Anti-inflammatory Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Anti-inflammatory: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Anti-inflammatory Market Size in 7MM
  • 13.3. Anti-inflammatory Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Anti-inflammatory Total Market Size in the United States
    • 15.1.2. Anti-inflammatory Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Anti-inflammatory Total Market Size in Germany
    • 15.3.2. Anti-inflammatory Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Anti-inflammatory Total Market Size in France
    • 15.4.2. Anti-inflammatory Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Anti-inflammatory Total Market Size in Italy
    • 15.5.2. Anti-inflammatory Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Anti-inflammatory Total Market Size in Spain
    • 15.6.2. Anti-inflammatory Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Anti-inflammatory Total Market Size in the United Kingdom
    • 15.7.2. Anti-inflammatory Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Anti-inflammatory Total Market Size in Japan
    • 15.8.3. Anti-inflammatory Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Anti-inflammatory

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.